Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Younes, A.
Right arrow Articles by Cabanillas, F.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Younes, A.
Right arrow Articles by Cabanillas, F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 8:S129-S131, 1997
© 1997 European Society for Medical Oncology

Paclitaxel (Taxol®) for the treatment of lymphoma

A. Younes1, J. P. Ayoub1, A. Sarris1, L. North2, O. Pate1, P. McLaughlin1, M. A. Rodriguez1, J. Romaguera1, F. Hagemeister1, C. Bachier1, A. Preti1 and F. Cabanillas1

1 Department of Hematology, Section of Lymphomas, University of Texas M. D. Anderson Cancer Center Houston, TX, USA
2 Division of Diagnostic Radiology, University of Texas M. D. Anderson Cancer Center Houston, TX, USA

1Correspondence to: Anas Younes, MD Section of Lymphoma (P.O. Box 68) University of Texas MD Anderson Cancer Center 1515 Holcombe Blvd Houston, TX 77030 USA

Pacitaxel (Taxol®) was recently tested in patients with relapsed and refractory lymphoma in two phase II clinical trials using two different infusion schedules. The first, reported from the NCI (USA), used a 96-hour intravenous continuous infusion schedule, and the second, from our group, used a 3-hour infusion. In the NCI trial, 29 evaluable patients were treated with 140 mg/m2 every three weeks, which achieved a 17% response rate (all PRs); while we treated 96 evaluable patients with 200 mg/m2 every three weeks, which achieved a 25% response rate (10 CRs and 14 PRs, 95% CI: 17%–35%). In our trial, patients with relapsed (not primary refractory) intermediate-grade lymphoma had a response rate of 50%, and those with relapsed lowgrade lymphoma had a response rate of 31%. In a follow-up trial, 12 patients who failed to respond to 3-hour infusion of paclitaxel were crossed over to receive pacitaxel by 96-hour infusion. None of the 12 evaluable patients achieved a major clinical response. Similarly, of 25 patients treated with cyclosporine A and paclitaxel after failing therapy with single-agent paclitaxel, only one patient (4%) responded. We conclude that paclitaxel has a promising single-agent activity, most prominently in patients with relapsed intermediate-grade lymphoma. Paclitaxel-based combination programs are currently being evaluated in our institution.

lymphoma, paclitaxel


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.